Johnson & Johnson MedTech has announced one-year clinical results for its Shockwave Javelin Peripheral IVL Catheter, a device designed to treat calcified, difficult-to-cross peripheral artery disease (PAD) lesions. The data were presented at the Vascular InterVentional Advances (VIVA) 2025 meeting. The studies included 110 patients with heavily calcified, stenotic peripheral arterial lesions, with an average lesion length of 77mm. At one year, the rate of major amputation was 1.0%, cardiovascular death was 3.9%, and the clinically-driven target lesion revascularization (CD-TLR) rate was 14.7%. Primary patency was reported at 72.7% for above-the-knee lesions and 61.5% for below-the-knee lesions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.